All types of drugs are expected to be affected to lesser or greater degrees by the COVID-19 outbreak in South Korea in 2020. Antiviral and respiratory drugs, along with those used for treating life-threatening conditions are expected to be the least affected. In contrast, drugs for non-urgent illnesses and conditions are expected to be most affected, as people stay away from hospitals if possible.
Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$149 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Impact of COVID-19 on revenue of hospitality and retail sector South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gwangju and Jeolla South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Daegu and Gyeongbuk South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Daejeon and Chungcheong South Korea 2020
- Premium Statistic Impact of COVID-19 on OTC pharmacy sales South Korea 2020
- Premium Statistic Changes in outpatient prescriptions during COVID-19 in Seoul South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Busan and Gyeongnam South Korea 2020
- Premium Statistic Impact of COVID-19 on pharmacy operations in South Korea 2020
About the region
10
- Basic Statistic Moderna Inc collaboration revenue by related party 2018-2022
- Basic Statistic R&D expenses of Moderna by type 2022
- Basic Statistic Moderna's revenue 2016-2022
- Basic Statistic Moderna total assets 2016-2022
- Basic Statistic Moderna net income 2016-2022
- Basic Statistic R&D expenses of Moderna 2016-2022
- Basic Statistic Merck & Co total assets 2009-2022
- Premium Statistic Amgen's expenditure on research and development 2006-2022
- Premium Statistic Top global biotech companies - net sales 2021
- Premium Statistic Top global biotech companies based on number of employees 2022
Selected statistics
10
- Basic Statistic Sanofi's total assets 2007-2022
- Premium Statistic Merck & Co - expenditure on research and development 2006-2022
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2022
- Basic Statistic GSK's operating profit by division 2006-2021
- Basic Statistic Merck & Co cash dividends declared 2006-2022
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2022
- Premium Statistic Sales of Johnson & Johnson 2006-2022 by region
- Premium Statistic Johnson & Johnson's number of employees 2004-2022
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2022, by segment
- Premium Statistic Global pharmaceutical pipeline by therapy area 2013-2017
Other regions
10
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Basic Statistic Revenue of leading European pharmaceutical markets 2021
- Premium Statistic Revenue value from biotechnology companies in Germany 2008-2021
- Premium Statistic Impact of COVID-19 on inbound tourist arrivals South Korea 2020
- Premium Statistic Market size of branded biopharmaceuticals in China 2013-2023
- Premium Statistic Leading pharmaceutical producing companies in Colombia 2021
- Premium Statistic Biotech industry growth rates in Australia compared to worldwide 2016
- Basic Statistic Pharmaceutical revenue as percent of health spending in African major countries 2014
- Basic Statistic Pharma sales as share of health spending in Latin America by major country 2014
- Premium Statistic Total equity of the Ipsen group 2014-2019
Related statistics
10
- Premium Statistic Changes in outpatient prescriptions in Gyeonggi/Incheon/Gangwon South Korea 2020
- Premium Statistic Sales revenue Yuhan 2015-2022
- Premium Statistic Traditional medicine industry sales in South Korea 2021, by sector
- Premium Statistic Traditional medicine industry South Korea 2021, by sales revenue
- Premium Statistic Number of companies in biotech industry in South Korea 2021, by sector
- Premium Statistic R&D investment value in biotech industry in South Korea 2021, by sector
- Premium Statistic Impact of COVID-19 on revenue of airlines and duty-free South Korea 2020
- Premium Statistic New pharmaceutical drugs in R&D pipelines in South Korea 2014, by therapeutic area
- Premium Statistic Anti-cancer drugs estimated market size in South Korea 2014-2020
- Premium Statistic Anti-diabetics estimated market size in South Korea 2014-2020
Further related statistics
10
- Celgene's revenue and net income 2006-2018
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
Further Content: You might find this interesting as well
Statistics
- Celgene's revenue and net income 2006-2018
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
IQVIA. (March 31, 2020). Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) [Graph]. In Statista. Retrieved December 06, 2023, from https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. "Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)." Chart. March 31, 2020. Statista. Accessed December 06, 2023. https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. (2020). Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won). Statista. Statista Inc.. Accessed: December 06, 2023. https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. "Adjusted Pharmaceutical Sales Forecast in South Korea in 2020, by Drug Type (in Billion South Korean Won)." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA, Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) Statista, https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/ (last visited December 06, 2023)
Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/